Publication: Inpatient prevalence, burden and comorbidity of Takayasu's arteritis: Nationwide inpatient sample 2013–2014
Issued Date
2019-08-01
Resource Type
ISSN
1532866X
00490172
00490172
Other identifier(s)
2-s2.0-85058637884
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Seminars in Arthritis and Rheumatism. Vol.49, No.1 (2019), 136-139
Suggested Citation
Patompong Ungprasert, Karn Wijarnpreecha, Wisit Cheungpasitporn, Charat Thongprayoon, Paul T. Kroner Inpatient prevalence, burden and comorbidity of Takayasu's arteritis: Nationwide inpatient sample 2013–2014. Seminars in Arthritis and Rheumatism. Vol.49, No.1 (2019), 136-139. doi:10.1016/j.semarthrit.2018.11.008 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51509
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Inpatient prevalence, burden and comorbidity of Takayasu's arteritis: Nationwide inpatient sample 2013–2014
Abstract
© 2018 Elsevier Inc. Objectives: To investigate the inpatient prevalence, characteristics and comorbidities of patients admitted with Takayasu's arteritis (TAK) in the United States (US). Methods: Patients with TAK were identified within the Nationwide Inpatient Sample (NIS) database of the years 2013 and 2014 using the respective ICD-9 diagnostic code. Data on patient characteristics, comorbidities, resource utilization and expenditures was collected. A propensity-matched cohort of individuals without TAK was also created from the same database to serve as comparators. Results: A total of 2840 patients with TAK were identified from the database, corresponding to an inpatient prevalence of 4.6 cases per 100,000 admissions. Compared to the propensity-matched cohort of individuals without TAK, patients with TAK were found to have significantly increased odds of stroke (adjusted odds ratio (aOR): 4.66, 95% CI: 2.10−10.31, p < 0.01), aortic aneurysm (aOR: 40.76, 95% CI: 9.13−181.7, p < 0.01), aortic valvulopathy (aOR: 4.92, 95% CI: 2.09−11.55, p < 0.01) and peripheral vascular disease (aOR: 4.41, 95% CI: 1.22−3.32, p < 0.01). However, the mortality was not significantly different (aOR: 1.44, 95% CI: 0.58−3.61, p = 0.43). After adjusting for confounders, patients with TAK displayed a mean additional $11,275 (95% CI, $4946−$17,603) for total hospital costs and a mean additional $45,305 (95% CI, $23,063−$67,546) for total hospitalization charges when compared to patients without TAK. Conclusions: The inpatient prevalence of TAK was higher than what would be expected from the overall incidence. The mean total hospital costs and total hospitalization charges for a patient admitted with TAK were higher than patients without TAK. Analysis of comorbidities found significantly higher odds of several vascular comorbidities compared with a propensity-matched cohort of individuals without TAK.